Highlights

  • Argenica Therapeutics, Rubicon Water and RBR Group recorded share price gains without new price-sensitive announcements.
  • The three companies operate across biotechnology, water technology and workforce services sectors.
  • Upcoming milestones include clinical updates, contract developments and operational progress.

Argenica Therapeutics (ASX:AGN), Rubicon Water (ASX:RWL) and RBR Group (ASX:RBR) moved higher on Friday, 25 September 2026, despite no new price-sensitive announcements from the companies.

The broader market was weaker during the session, while smaller companies with lower trading Liquidity can experience larger percentage movements from limited buying activity.

Argenica Therapeutics (ASX:AGN)

Argenica Therapeutics closed at AUD 0.15 on 25 September 2026, up 20.00% during the session.

The company is a biotechnology Business developing neuroprotective treatments. Its lead candidate, xaranetide (formerly ARG-007), is designed to protect brain cells following acute injury.

Argenica reported that its Phase 2 stroke trial in patients undergoing clot removal achieved its primary safety endpoint.

Recent company filings were routine and included updates regarding a planned presentation of preclinical concussion data at the International NeuroTrauma Society 2026 meeting and the company’s Annual General Meeting arrangements.

The company reported approximately $6.36 million in cash at 30 June 2026.

What to watch

  • Presentation of concussion research data at the October 2026 conference.
  • Updates regarding regulatory discussions.
  • Further development plans for xaranetide clinical trials.

Rubicon Water (ASX:RWL)

Rubicon Water closed at AUD 0.30 on 25 September 2026, up 27.08% during the session.

The company develops irrigation automation technology, including systems designed to manage water flows and improve irrigation efficiency.

Rubicon Water’s products include Total Channel Control systems and FlumeGate technology, with installations across multiple countries.

The company reported FY26 Revenue of $61.1 million and a net loss of $15.7 million, with management attributing part of the result to delays in US federal funding.

Rubicon also reported Operating Cash Flow of $4.5 million and an advanced-stage project pipeline.

The company received an ASX price query following its share price movement and stated that it was not aware of any undisclosed information explaining the trading activity.

What to watch

  • Progress converting the project pipeline into contracts.
  • Operational updates under new CFO leadership.
  • Further developments in water technology markets.

RBR Group (ASX:RBR)

RBR Group closed at AUD 0.016 on 25 September 2026, up 6.67% during the session.

The company provides workforce training, skilled labour and accommodation services through its Mozambique-based Futuro Group subsidiary.

RBR Group’s business outlook is linked to developments around the Mozambique LNG project, where the company has pursued opportunities for training, labour and camp services.

Recent company filings were related to Capital Structure matters, including the issue of shares to settle convertible note obligations.

The company continues monitoring opportunities associated with Mozambique LNG-related activities.

What to watch

  • Potential contract awards linked to Mozambique LNG.
  • Further updates from Futuro Group operations.
  • Future funding and corporate developments.

The bigger picture

Argenica Therapeutics, Rubicon Water and RBR Group operate across different sectors, including biotechnology, water infrastructure technology and workforce services.

Their share price movements can be influenced by company developments, liquidity conditions, market sentiment and investor positioning.

Future progress will depend on clinical milestones, commercial execution and operational developments.